Maze Therapeutics, Inc. Common Stock MAZE
i
Market datapartial · fetched 2026-11-04T00:45:46.363Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T21:00:04.396558478Z
FundamentalsAlpha Vantage · unavailable
Maze Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 25.81 | 150.0% | 24.2% | |||
| 25Δ | 27.26 | 144.6% | 21.0% | |||
| 30Δ | 28.71 | 139.2% | 17.8% | |||
| 35Δ | 40.84 | 184.4% | 34.2% | 30.10 | 133.5% | 14.7% |
| 40Δ | 34.48 | 82.9% | 11.7% | 30.96 | 125.1% | 12.8% |
| 45Δ | 33.77 | 80.9% | 10.3% | 31.83 | 116.6% | 10.9% |
| 50Δ | 33.06 | 78.9% | 8.9% | 32.70 | 108.2% | 9.0% |
| 55Δ | 32.34 | 76.9% | 7.6% | 33.56 | 99.8% | 7.1% |
| 60Δ | 31.63 | 74.8% | 6.2% | 34.43 | 91.4% | 5.3% |
| 65Δ | 30.91 | 72.8% | 4.8% | 35.41 | 86.2% | 3.8% |
| 70Δ | 30.20 | 70.8% | 3.5% | 36.60 | 87.1% | 3.1% |
| 75Δ | 37.79 | 88.0% | 2.5% | |||
| 80Δ | 38.98 | 88.9% | 1.8% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 25.81
- IV
- 150.0%
- B/E move
- 24.2%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 27.26
- IV
- 144.6%
- B/E move
- 21.0%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 28.71
- IV
- 139.2%
- B/E move
- 17.8%
35Δ
- Pseudo strike
- 40.84
- IV
- 184.4%
- B/E move
- 34.2%
- Pseudo strike
- 30.10
- IV
- 133.5%
- B/E move
- 14.7%
40Δ
- Pseudo strike
- 34.48
- IV
- 82.9%
- B/E move
- 11.7%
- Pseudo strike
- 30.96
- IV
- 125.1%
- B/E move
- 12.8%
45Δ
- Pseudo strike
- 33.77
- IV
- 80.9%
- B/E move
- 10.3%
- Pseudo strike
- 31.83
- IV
- 116.6%
- B/E move
- 10.9%
50Δ
- Pseudo strike
- 33.06
- IV
- 78.9%
- B/E move
- 8.9%
- Pseudo strike
- 32.70
- IV
- 108.2%
- B/E move
- 9.0%
55Δ
- Pseudo strike
- 32.34
- IV
- 76.9%
- B/E move
- 7.6%
- Pseudo strike
- 33.56
- IV
- 99.8%
- B/E move
- 7.1%
60Δ
- Pseudo strike
- 31.63
- IV
- 74.8%
- B/E move
- 6.2%
- Pseudo strike
- 34.43
- IV
- 91.4%
- B/E move
- 5.3%
65Δ
- Pseudo strike
- 30.91
- IV
- 72.8%
- B/E move
- 4.8%
- Pseudo strike
- 35.41
- IV
- 86.2%
- B/E move
- 3.8%
70Δ
- Pseudo strike
- 30.20
- IV
- 70.8%
- B/E move
- 3.5%
- Pseudo strike
- 36.60
- IV
- 87.1%
- B/E move
- 3.1%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 37.79
- IV
- 88.0%
- B/E move
- 2.5%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 38.98
- IV
- 88.9%
- B/E move
- 1.8%
Options history
Table
| Date | IV (%) |
|---|---|
| 68.68% | |
| 68.49% | |
| 64.81% | |
| 64.80% | |
| 68.84% | |
| 74.84% | |
| 72.36% | |
| 73.43% | |
| 74.58% | |
| 72.31% |
Biotechnology
MBX
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and…
More →MCRB
Seres Therapeutics, Inc., a microbiome therapeutic platform company, is involved in the development of bacterial consortia that are designed to functionally interact with host…
More →MDGL
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of…
More →MDWD
Description unavailable
More →MDXG
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company is headquartered in Marietta, Georgia.
More →MESO
Description unavailable
More →